Abstract: The present invention relates to a method for preventing or treating obesity, diabetes, dyslipidemia, fatty liver or insulin resistance syndrome, comprising: administering to a mammalian subject in need thereof a therapeutically effective amount of a composition comprising adipic acid. The present composition containing adipic acid as an active ingredient is very effective in preventing or treating obesity, diabetes, dyslipidemia, fatty liver (preferably, non-alcoholic fatty liver) or insulin resistance syndrome. The composition of the present invention useful as pharmaceuticals compositions or functional food compositions has therapeutic efficacies for obesity, dyslipidemia or fatty liver, and also induces significant decrease in fasting glucose level and blood insulin level to improve type 2 diabetes, insulin resistance and related metabolic diseases.

Abstract: The present invention relates to a method for preventing or treating obesity, diabetes, dyslipidemia, fatty liver or insulin resistance syndrome, comprising: administering to a mammalian subject in need thereof a therapeutically effective amount of a composition comprising adipic acid. The present composition containing adipic acid as an active ingredient is very effective in preventing or treating obesity, diabetes, dyslipidemia, fatty liver (preferably, non-alcoholic fatty liver) or insulin resistance syndrome. The composition of the present invention useful as pharmaceuticals compositions or functional food compositions has therapeutic efficacies for obesity, dyslipidemia or fatty liver, and also induces significant decrease in fasting glucose level and blood insulin level to improve type 2 diabetes, insulin resistance and related metabolic diseases.

Abstract: The present invention relates to a diagnostic kit for metabolic diseases selected from the group consisting of obesity, dyslipidemia, fatty liver, and insulin resistance syndrome, and a method for screening a therapeutic composition for said diseases. The invention provides a large number of new gene targets for metabolic diseases such as obesity and the like, thereby enabling a more reliable diagnosis of genes such as obesity and the like and the use in the screening of a therapeutic candidate material based on the new gene targets.

Abstract: Disclosed is a composition for preventing or treating obesity, dyslipidemia, fatty liver or diabetes, containing an indole-3-carbinol derivative as an active ingredient. The indole-3-carbinol derivative of the present disclosure can be usefully used as a pharmaceutical or functional food composition for preventing or treating obesity, dyslipidemia, fatty liver or diabetes by inhibiting differentiation of preadipocytes and reducing accumulation of triglyceride in cells.

Abstract: Disclosed is a composition including camphene as an active ingredient for preventing or treating obesity, dyslipidemia, fatty liver or insulin resistance syndrome. The composition of the present disclosure including camphene as an active ingredient suppresses differentiation of adipocytes, reduces body fat, reduces visceral fat, reduces total cholesterol level, reduces serum triglyceride level and reduces liver tissue triglyceride level, and thus exhibits preventive or therapeutic activity for obesity, hyperlipidemia or fatty liver. Furthermore, the composition of the present disclosure exhibits the effect of improving type 2 diabetes or insulin resistance and related metabolic disease by significantly reducing fasting blood sugar level and blood insulin level.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating hyperlipidemia, fatty liver, diabetes and obesity comprising a sesquiterpene derivative as an active ingredient. The sesquiterpene derivatives of the present invention leads to decrease in body fat weight, visceral fat weight and total cholesterol levels, triglyceride of plasma and liver tissue, blood glucose and blood insulin levels in a fast state, finally exhibiting efficacies on prevention or treatment of hyperlipidemia, fatty liver, diabetes and obesity.

Abstract: Provided is a composition for the prevention or treatment of obesity, dyslipidaemia, fatty liver or insulin resistance syndrome, comprising piperonal as an active ingredient. The composition of the present invention can be used to advantage as a drug or functional food composition which not only exhibits activity in the prevention or treatment of obesity, hyperlipidaemia or fatty liver but which also causes a significant reduction in fasted blood sugar and blood insulin concentration and hence has an effect in improving Type-2 diabetes or insulin resistance and also improves metabolic disorder which is closely associated therewith.

Abstract: The present invention relates to a novel use for the compound of Chemical formula 1 in order to produce drugs or foods for the prevention or treatment of obesity, fatty liver, diabetes, metabolic syndrome or the like, and to a composition for the prevention or treatment of obesity, fatty liver, diabetes, metabolic syndrome or the like which contains the compound of Chemical formula 1 as an active ingredient, and also to a method for the prevention or treatment of obesity, fatty liver, diabetes, metabolic syndrome or the like comprising the administration of the compound of Chemical formula 1 to a mammal in a therapeutically effective dose.

Abstract: The present invention relates to a composition for preventing or treating obesity, dyslipidemia, fatty liver or insulin resistance syndrome, comprising cinchonine as an active ingredient. The composition of the present invention comprising cinchonine as an active ingredient contributes to not only inhibition of adipocyte differentiation but also reductions of body weight, visceral fat, total cholesterol level, plasma triglyceride level and liver tissue triglyceride level, thereby exerting prevention or treatment efficacies of obesity, hyperlipidemia or fatty liver. In addition, the composition of the present invention induces significant decrease in fasting glucose level and blood insulin level to improve type 2 diabetes, insulin resistance and related metabolic diseases.

Abstract: The present invention relates to a method for preventing or treating obesity, diabetes, dyslipidemia, fatty liver or insulin resistance syndrome, comprising: administering to a mammalian subject in need thereof a therapeutically effective amount of a composition comprising adipic acid. The present composition containing adipic acid as an active ingredient is very effective in preventing or treating obesity, diabetes, dyslipidemia, fatty liver (preferably, non-alcoholic fatty liver) or insulin resistance syndrome. The composition of the present invention useful as pharmaceuticals compositions or functional food compositions has therapeutic efficacies for obesity, dyslipidemia or fatty liver, and also induces significant decrease in fasting glucose level and blood insulin level to improve type 2 diabetes, insulin resistance and related metabolic diseases.

Abstract: The present invention relates to a method for preventing or treating dyslipidemia or fatty liver, comprising: administering to a mammalian subject in need thereof a therapeutically effective amount of a composition comprising nonenal. The present composition containing nonenal as an active ingredient is very effective in preventing or treating obesity, diabetes, dyslipidemia, fatty liver or insulin resistance syndrome (preferably, dyslipidemia or fatty liver, more preferably hyperlipidemia or fatty liver). The composition of the present invention useful as pharmaceuticals compositions or functional food compositions has therapeutic efficacies for obesity, diabetes, hyperlipidemia or fatty liver, and also induces significant decrease in fasting glucose level and blood insulin level to improve type 2 diabetes, insulin resistance and related metabolic disorders.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating hyperlipidemia, fatty liver, diabetes and obesity comprising a sesquiterpene derivative as an active ingredient. The sesquiterpene derivatives of the present invention leads to decrease in body fat weight, visceral fat weight and total cholesterol levels, triglyceride of plasma and liver tissue, blood glucose and blood insulin levels in a fast state, finally exhibiting efficacies on prevention or treatment of hyperlipidemia, fatty liver, diabetes and obesity.

Abstract: Disclosed is a composition including camphene as an active ingredient for preventing or treating obesity, dyslipidemia, fatty liver or insulin resistance syndrome. The composition of the present disclosure including camphene as an active ingredient suppresses differentiation of adipocytes, reduces body fat, reduces visceral fat, reduces total cholesterol level, reduces serum triglyceride level and reduces liver tissue triglyceride level, and thus exhibits preventive or therapeutic activity for obesity, hyperlipidemia or fatty liver. Furthermore, the composition of the present disclosure exhibits the effect of improving type 2 diabetes or insulin resistance and related metabolic disease by significantly reducing fasting blood sugar level and blood insulin level.

Abstract: The present invention is related to novel use of piperine, and more specifically, it is related to a pharmaceutical or food composition for preventing and treating obesity comprising piperine or a salt thereof as an active ingredient. The present invention is related to novel use of piperine, and it provides a pharmaceutical or food composition for preventing and treating obesity comprising piperine or a salt thereof as an active ingredient. The composition comprising piperine of the present disclosure is effective on suppression of abdominal fat accumulation and body weight loss. Therefore, the composition can be effectively used to prevent and treat obesity.

Abstract: Disclosed is an use of Spanish oregano (Thymus capitatus) extract, summer savory (Satureja hortensis) extract or carvacrol for treating metabolic diseases. More specifically, the present disclosure relates to a composition containing Spanish oregano extract or summer savory extract, carvacrol, which is an aromatic oil component frequently found in mint, oregano, thyme, bergamot camphor tree or thyme thymol, as an active ingredient, for preventing and treating a metabolic disease selected from the group consisting of obesity, fatty liver, hyperlipidemia and diabetes, an use thereof, and a method of using the same. The disclosed composition, use and method are useful for weight loss, suppression of abdominal fat accumulation, treatment of fatty liver, reduction of cholesterol and free fatty acid in plasma and liver tissue, and improvement of blood glucose level and insulin resistance.